HIV Drug Therapy Latest News2003-12-13T18:30:02Zhivdrugtherapy.orgurn:uuid:60a76c80-d399-11d9-b93C-0003939e0af6<strong>Drug Interactions</strong> - DRV/r and Pravastatin<br /><div><strong>Case Report</strong> – Nevirapine and quinine.<br /></div><strong>Drug Interactions</strong> - Combined oral contraceptives and ART<br /><div><strong>Review</strong> - Update on drug interactions.</div><div><strong>Drug Interactions</strong> - Buprenorphine and DRV/r or FPV/r.</div><div><strong>Drug Interactions</strong> - New studies on efavirenz and rifampicin.</div><div><strong>Case Reports</strong> - Contraceptive failure with etonogestrel implants and efavirenz.</div><div><strong>Drug Interactions</strong> - Sirolimus (rapamycin) and ART.</div><div><strong>Review</strong> - Interactions between antiretrovirals and complementary and African traditional medicines.</div><div><strong>Drug Interactions</strong> - Nevirapine and artemether/lumefantrine.</div><div><strong>Drug Interactions</strong> - Rifampicin and once daily efavirenz or nevirapine.</div><div><strong>Meeting Report</strong> - 13th European AIDS Conference/EACS, Belgrade.</div><div><strong>Review</strong> - Drug Interactions in Infectious Diseases</div><div><strong>Meeting Report</strong> - 51st ICAAC, Chicago.</div><div><strong>Review</strong> - HIV and malaria.</div><div><strong>Review</strong> - Drug transporters and protease inhibitor pharmacokinetics and interactions.</div><div><strong>Review</strong> - Treatment of major depressive disorder in HIV+ subjects.</div><div><strong>Drug Interactions</strong> - Autoinduction and CYP2B6 genotype with efavirenz and rifampicin.</div><div><strong>New Drugs</strong> - Boosting of atazanavir by cobicistat.</div><div><strong>Drug Interactions</strong> - DRV/r and rosuvastatin.</div><div><strong>Meeting Report</strong> - 6th IAS Conference, Rome.</div><div><strong>Drug Interactions</strong> - Rifabutin and ATV/r in healthy subjects.</div><strong>Drug Interactions </strong>- Effect on darunavir and tipranavir concentrations when switching from enfuviritide to raltegravir. <strong>Drug Interactions</strong> - Lopinavir and rifampicin in HIV+ subjects.<strong>Case Reports</strong> – Cushing’s syndrome with atazanavir/ritonavir <div><strong>Drug Interactions</strong> - Dolutegravir (S/GSK1349572) with multivitamins or acid reducing agents.</div><div><strong>Drug Interactions</strong> - Maraviroc with etravirine and darunavir/ritonavir.</div><div><strong>Review </strong>- Elvitegravir pharmacokinetics and interactions.</div><strong>Case Reports</strong> - ART and acenocoumarol or statins <div><strong>Drug Interactions</strong> - Predictors of clinically significant interactions.</div><div><strong>Meeting Report</strong> - 12th Pharmacology Workshop, Miami.</div><div><strong>Drug Interactions</strong> - Atazanavir/ritonavir and combined oral contraceptives.</div><div><strong>Review</strong> - Tranporter-mediated interactions</div><strong>Case Report</strong> – Extreme bradycardia with lopinavir/ritonavir and metoprolol and lacidipine. <div><strong>Review</strong> - Dolutegravir (S/GSK1349572), a new integrase inhibitor.</div><div><strong>Drug Interaction</strong> - Raltegravir and oral contraceptives.</div><div><strong>Pharmacokinetics</strong> - In silico prediction of efavirenz/rifampicin interaction.</div><div><strong>Meeting Report</strong> - 18th CROI, Boston</div><div><strong>Case Report</strong> - Voriconazole with once daily darunavir/ritonavir and twice daily etravirine.</div><div><strong>Drug Interactions</strong> - Rifabutin and saquinavir/ritonavir.</div><div><strong>Drug Interactions</strong> - Emerging antiretroviral drug interactions</div><div><strong>Drug Interactions</strong> - NNRTIs and TB therapy</div><div><strong>Drug Interactions</strong> - ARVs and targeted cancer therapies</div><div><strong>Review</strong> - Etravirine interactions.</div><div><strong>Review</strong> - Management of TB/HIV coinfection</div><div><strong>Drug Interactions</strong> - Raltegravir and unboosted atazanavir</div><div><strong>Review </strong>- Herb-drug interactions</div><div><strong>Review</strong> - Drug-drug interactions in HIV infection.</div><div><strong>Drug Interactions</strong> - November issue of Clinical Pharmacology & Therapeutics</div><div><strong>Drug Interactions</strong> - Raltegravir and antacids.</div><div><strong>Review</strong> - Etravirine pharmacokinetics</div><div><strong>Drug Interactions</strong> - Etravirine, raltegravir, darunavir/ritonavir</div><div><strong>Meeting Report</strong> - HIV10, Glasgow, November 2010</div><div><strong>Drug Interactions</strong> - Lopinavir/r and a contraceptive patch</div><div><strong>Drug Interaction</strong> - Efavirenz and bexarotene</div><div><strong>Drug Interactions</strong> - Darunavir/r and rifabutin</div><div><strong>Drug Interactions</strong> - Lopinavir and BILR 355/ritonavir</div><div><strong>Drug Interactions</strong> - Posaconazole to boost fosamprenavir.</div><div><strong>Pharmacokinetics</strong> - elvitegravir, tenofovir and emtricitabine with ritonavir or cobicistat.</div><div><strong>Review</strong> - Interactions with rosuvastatin.</div><div><strong>Drug Interactions</strong> - Oxycodone and ritonavir or lopinavir/ritonavir.</div><div><strong>Meeting Report</strong> - 50th ICAAC, Boston, September 2010.</div><div><strong>Drug Interactions</strong> - Vinblastine and boosted PIs.</div><div><strong>Drug Interactions</strong> - Rifampicin and lopinavir in children.</div><div><strong>Review</strong> - Raltegravir.</div><div><strong>Drug Interactions</strong> - Buprenorphine/naloxone and once daily lopinavir/ritonavir.</div><div><strong>Correspondence</strong> - Switching from efavirenz to nevirapine.</div><strong>Review</strong> - Managing drug interactions. <div><strong>Meeting Report</strong> - 18th World AIDS Conference, Vienna.</div><strong>Pharmacokinetics</strong> – Once daily darunavir/ritonavir and efavirenz <strong>Review</strong> – Effect of herbals on drug absorption <strong>Case report</strong> – lack of PK interaction between bosentan and nevirapine <strong>Webcast</strong> – PK and Drug Interactions. Review - MaravirocPharmacokinetics - Darunavir/ritonavir and hepatic impairment.Review - QT interval prolongationDrug Interactions - Use of the website to determine prevalence of drug interaction in the Swiss HIV Cohort.Herbals - Effect of danshen on CYP3A4Drug Interactions - Prevalence of clinically significant interactions in a clinical cohort.Drug Interactions - Lersivirine and antacids.Review - Intracellular pharmacokinetics of antiretrovirals.Meeting Report - 11th PK Workshop, Sorrento, April 2010.Case Reports - IV docetaxel and ritonavir.Review - Warfarin and antiretrovirals.Review - Management of HIV/TB co-infection.Drug Interactions - Ritonavir and quinine.Drug Interactions - Tenofovir and boosted or unboosted fosamprenavir.Drug interactions - Combined administration of potent CYP3A inducers and inhibitors.Meeting Report - Drug interactions at 17th CROI.Drug Interaction - Elvitegravir/ritonavir and maraviroc.Drug Interactions - Nevirapine and atazanavirReview - Treating HIV/AIDS and substance abuse.Review - HIV internet resources.Review - Antiretrovirals and the kidney.Drug Interactions - Maraviroc and raltegravir.Drug Interactions - GS-9350 and midazolamReview - Comment on review by Brown et al.Review - Vicriviroc.Case Reports - Quetiapine and atazanavir/ritonavir.Drug Interactions - Tipranavir/ritonavir and efavirenz.Drug Interactions - Rifabutin and lopinavir/ritonavir.Drug Interactions - Tipranavir/ritonavir and statins.Meeting Report - 12th EACS, Cologne, November 2009.Review - Pharmacokinetics and interactions of new antiretrovirals.Drug Interactions - Raltegravir/etravirine clinical trial data.Webcast - HIV and AgeingDrug Interactions - Lopinavir and gemfibrozil.Drug Interactions - Etravirine after stopping efavirenz.Drug Interactions - Efavirenz and rifampicin in South Africans.Drug Interactions - Raltegravir and lamotrigine.Drug interactions - Ritonavir and albendazole or mebendazole.Meeting Report - 49th ICAAC, San Francisco, September 2009.Herbals - Updated review on interactions.Review - EtravirineDrug Interactions - Interactions with immunosuppressants.Drug Interactions - Raltegravir and darunavir/ritonavir or rifampicin.Herbals - Korean Red GinsengCase Report - Ritonavir and triamcinolone.Drug Interaction - Nevirapine and darunavir/ritonavir.Drug Interactions - Docetaxel and ritonavir (100 mg).Drug Interactions - Posaconazole with ATV, ATV/r or EFV.Drug Interactions - Saquinavir concentrations with 50 mg ritonavir in Thai patients.Webcasts - PK Presentations from IAS 2009.Drug Interaction - Darunavir and nevirapine.Meeting Report - 5th IAS Conference, Cape Town, July 2009.Drug Interactions - Rifampicin and NNRTIsDrug Interaction - Artemether/lumefantrine and lopinavir.Drug Interaction - More on raltegravir and etravirine.Drug Interaction - Raltegravir and immunosuppressants.Review - Interactions with new and investigational antiretrovirals.Drug Interactions - Ginkgo and efavirenz.Case Reports - Development of resistant TB with rifabutin and boosted protease inhibitors.Case Reports - Etravirine-Raltegravir interaction.Drug Interactions - Correspondence on interactions with rifampicin.Review - DarunavirCase Reports - Difficult Pharmacology Case Presentations from BHIVA meetingDrug Interaction Alert - Swine FluReview - EtravirineMeeting Report – 10th Pharmacology Workshop, Amsterdam, April 2009. Case Report - Darunavir/ritonavir and tacrolimus interaction.Drug Interactions - Efavirenz and rifampicin in children.Review - RaltegravirWebcasts – Presentations on drug interactionsDrug Interactions - Rifampicin and atazanavir/ritonavir.Drug Interactions - Raltegravir and omeprazole.Drug Interactions - Saquinavir/ritonavir and ketoconazole.Drug Interactions - Dose response of ritonavir on elvitegravir exposure.Drug Interactions - Tipranavir/ritonavir and clarithromycin, fluconazole or rifabutin.Drug Interactions - Article and presentation on interactions with newer antiretroviralsMeeting Report - 16th CROI, Montreal, February 2009.Case Report - Use of TDM to manage the efavirenz-rifampicin interaction.Case report - Protease inhibitors and Cat's claw.Review - Interactions with statins and ART.Review - Drug interactions with new antiretrovirals.Drug Interactions - Raltegravir and etravirine.Review - Interactions with antifungalsDrug Interactions - Lack of interaction between elvitegravir/ritonavir and etravirine.Drug Interactions - Raltegravir and ritonavir or efavirenzDrug Interactions - Hyperbilirubinaemia with atazanavir and ribavirinReview - Interactions with integrase inhibitors.Meeting Report - HIV9, Glasgow, November 2008.Drug Interactions - Elvitegravir with tipranavir/ritonavir or darunavir/ritonavir.Drug Interactions - Effect on tacrolimus when switching from nelfinavir to fosamprenavir.Drug Interactions - Efavirenz and ItraconazoleMeeting Report - 48th ICAAC, Washington, October 2008Drug Interactions - Key papers on methadone and ritonavir.Drug Interactions - Atazanavir/ritonavir with minocyline and valproic acidDrug Interactions - Predicting interactions with maravirocNew BHIVA guidelines recommend discussion with all patients on potential of HIV treatment to protect sexual partnersThe British HIV Association today recommends that doctors
should discuss the evidence for the effectiveness of antiretroviral treatment as
prevention with all patients with HIV, and that it should be offered those who
want to protect their partners from the risk of HIV infection – even if they
have no immediate clinical need forhttp://www.aidsmap.com/New-BHIVA-guidelines-recommend-discussion-with-all-patients-on-potential-of-HIV-treatment-to-protect-sexual-partners/page/2235411/US CDC recommends HPV vaccine for young menYoung men and adolescent boys between the ages of 11 and 21
should be vaccinated against human papillomavirus, the cause of genital warts,
anal and cervical cancer, the Advisory Committee on Immunization Practices has
recommended, in a new Adult Immunization Schedule published in Annals of Internal Medicine.
The committee also recommends that all gayhttp://www.aidsmap.com/US-CDC-recommends-HPV-vaccine-for-young-men/page/2235492/Gardasil protects against recurrence of pre-cancerous anal lesions in HIV-negative gay menThe genital wart
vaccine Gardasil significantly
reduces the risk of high-grade pre-cancerous anal lesion recurrence in men who
have sex with men, US investigators report in the online edition of Clinical Infectious Diseases.
The vaccine reduced
the risk of lesion recurrence by approximately 50% in the first two years after
immunisation. There was some evidence thathttp://www.aidsmap.com/Gardasil-protects-against-recurrence-of-pre-cancerous-anal-lesions-in-HIV-negative-gay-men/page/2234343/For patients with HIV viral load is key in immune response to yellow fever vaccineViral load is the only factor associated
with a poorer antibody response to the yellow fever vaccine in patients with
HIV, according to a French study published in the online edition of the Journal of Acquired Immune Deficiency
Syndromes.
For patients vaccinated after diagnosis
with HIV, an undetectable viral load was the “unique determinant” ofhttp://www.aidsmap.com/For-patients-with-HIV-viral-load-is-key-in-immune-response-to-yellow-fever-vaccine/page/2229704/Contraception in HIV prevention trials: injectable hormonal methods more effective?Women
using injectable (hormonal) contraceptives had a significantly lower rate of
pregnancy compared to those using oral contraception in a major HIV prevention study, researchers report in the advance online edition of AIDS.
However, the same study also found that women who used an injectable hormonal contraceptive method were at higher risk ofhttp://www.aidsmap.com/Contraception-in-HIV-prevention-trials-injectable-hormonal-methods-more-effective/page/2229312/Men who have sex with men may now be the highest-risk group for HIV in Africa, IAVI study suggestsMen who have sex with men may now be at considerably higher
risk of acquiring HIV than other at-risk groups such as female sex workers or
young people of either sex, if findings by the International AIDS Vaccine
Initiative (IAVI) of HIV incidence at two centres in Kenya can be generalised to other
populations.
Thehttp://www.aidsmap.com/Men-who-have-sex-with-men-may-now-be-the-highest-risk-group-for-HIV-in-Africa-IAVI-study-suggests/page/2234346/HIV care providers in US struggling to cope with rising patient numbersHIV doctors in the US are struggling to
meet the demands of a rising patient caseload, according to the findings of a
national survey.
Two-thirds of HIV treatment providers
reported an increase in patient numbers, and a third reported difficulties
being reimbursed for the care they provided.
The second annual HealthHIV State of Primaryhttp://www.aidsmap.com/HIV-care-providers-in-US-struggling-to-cope-with-rising-patient-numbers/page/2232782/Quarter of men resume sex before wounds from circumcision fully healed in Zambian studyApproximately a quarter of men undergoing circumcision
resume sexual activity before their wounds have fully healed, Zambian research
published in the online edition of AIDS
shows.
Most of the men reporting the early resumption of sexual
activity engaged in unprotected sex, often with multiple partners.
The investigators calculated that early resumption of sexual
activity at thishttp://www.aidsmap.com/Quarter-of-men-resume-sex-before-wounds-from-circumcision-fully-healed-in-Zambian-study/page/2227154/Raltegravir/Truvada HIV PEP regimen well tolerated with no infections after its useRaltegravir could have a “useful” role in HIV post-exposure
prophylaxis, according to investigators from the US writing in the online
edition of the Journal of Acquired Immune
Deficiency Syndromes.
Doctors in Boston, Massachusetts, prescribed a post-exposure
prophylaxis (PEP) regimen of raltegravir (Isentress)
with tenofovir and FTC (Truvada) to
100 patients after possible sexual exposure to HIV.http://www.aidsmap.com/RaltegraviriTruvadai-HIV-PEP-regimen-well-tolerated-with-no-infections-after-its-use/page/2227321/For study participants, PrEP was an opportunity to save their relationshipSeeking to understand why adherence to pre-exposure
prophylaxis (PrEP) was extremely high in a study of serodiscordant couples,
qualitative researchers have found that trial participants saw PrEP as a way
they could preserve their relationship despite the pressures created by the
knowledge of different HIV status and the risk of infection. In an article
publishedhttp://www.aidsmap.com/For-study-participants-PrEP-was-an-opportunity-to-save-their-relationship/page/2229616/